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Abstract
The essay, dedicated to Academician Drago Iki}–a pioneer in the de-
velopment and preparation of vaccines for prevention of infectious diseases
–at the occasion of his 95th birthday, discusses the relative failure of thera-
peutic vaccination for malignant diseases. From a personal perspective, the
author recounts the historic examples of »spontaneous« tumor regressions in
conjunction with acute infections; development of the first marketed pur-
portedly antigen–specific cellular immunotherapy (for metastatic prostate
cancer); the paradox of immunotherapy effect on overall survival, but not
on time to disease progression; and the promise of the new complex sys-
tems–based approaches to a more rational design of cellular immuno-
therapy in the hope of bringing this mode of treatment into the therapeutic
mainstream and standard of care.
Celebration of Academician Drago Iki}’s remarkable life and achieve-
ments in prophylactic immunology and immunotherapy provides an
opportunity to muse on the reasons why cellular immunotherapy of
cancer is less remarkable. As a latecomer to the field I enjoy the benefit
of hindsight and realization that the (empirical) quest to harness
immunity in control of malignancy is centuries older than immuno-
logy itself (cf. ref. 35). Yet, recognition that a tumor can be immunologi-
cally distinct from its tissue of origin is rather recent (cf. ref. (11)); it
prompted the idea of immune surveillance, the mechanism whereby
immunity constantly surveys the organism for damaged, diseased and
malignant cells and eliminates them (11). Hence, the rise of malignan-
cy implies the downfall of immunity. As a result, immunity must be
stimulated if it is to be counted on as a component of tumor therapy.
Despite this rational underpinning, more than half a century of con-
certed effort to develop immune therapies has documented a history of
failure that stands in sharp contrast with the magnificent achievement
in prophylactic vaccination against infectious disease; those in im-
munotherapy of cancer stay humble in the shadow of the celebrant and
his generation.
It is becoming increasingly clear that the reductionist views of the
20th century could not account for the complexity of interactions of the
tumor and immunity, two evolving subsystems that exhibit selective
pressure on each other. In distinction to antibiotics, (previously) consi-
dered as magic bullets against infectious agents, it is unlikely that
immunological magic for cancer is on the horizon. (For an insightful
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view of the concept of the magic bullet, cf. ref. (62)). A
major difference is that mechanisms of cancer immuno-
therapy are indirect, i.e., unlike antibiotics they are not
directed at cancer cells themselves, but at stimulating
immunity to recognize and eliminate such cells. Thus,
the required mechanism includes recognition of cancer
and its elimination. The cells that can eliminate other
cells cannot recognize the tumor on their own. First they
must be »taught« to do so by specialized »teacher« cells.
»Teaching« requires capture of the tumor cell (or, more
generally, pathogens) and the subsequent clonal activa-
tion and expansion of tumor–specific effector cells (cf.
any recent immunology textbook).
Boon of dendritic cells
Pathogen capture and processing are functions of in-
nate immunity; stimulation of clonal expansion of im-
mune effector cells is characteristic of acquired immu-
nity. How the cells of innate immunity instruct the cells
of acquired immunity was unclear until 1974 when Ralph
Steinman and Zanvil Cohn reported the finding of the
cell they named »dendritic« for the appearance of branch-
ed protrusions (Fig. 1) (61). In the course of activation,
dendritic cells (DCs) capture and process antigen and
later, having lost that capacity, they acquire the ability to
activate naïve and memory T (and other) cells (Fig. 1) in
antigen–specific manner (5). Later proven the most
potent antigen-presenting cells hitherto discovered, den-
dritic cells have been actively studied, in large part becau-
se of their postulated use as immune therapeutics. This
possibility gave rise to start-up companies developing
technologies for dendritic cell preparation, »education«
by antigen and testing in clinical studies.
It took almost twenty years to achieve the purported
triumph in the quest to use dendritic cells as therapeu-
tics. It came in 2010 as the approval in the United States
of sipuleucel-T (Provenge®, Dendreon, Seattle, WA) for
treatment of castration resistant metastatic prostate cancer.
The event has been viewed as a milestone in develop-
ment of cellular immunotherapy of cancer (18) that has
reinvigorated interest in vaccination therapy of cancer, a
field that earlier had lost its luster due in part to the
absence of significant clinical progress and in part to the
drying up of venture capital for funding early clinical
trials. The new energy in the field has been recognized
also by the 2011 Nobel Prize in Physiology or Medicine
for the discovery of dendritic cells to Ralph Steinman,
announced just days after his untimely death (50).
The lesson of lymphoma
The long effort to clinical and commercial develop-
ment of therapeutic cancer vaccines started with an earli-
er landmark, the success of dendritic cell vaccination of
patients suffering from B-cell lymphoma. In 1996, Ro-
nald Levy and colleagues at Stanford University treated
four patients with patient’s own dendritic cells »educat-
ed« by own monoclonal immunoglobulin receptor (mo-
noclonal origin of the receptor results from the mono-
clonal nature of the disease) (37). They selected the
monoclonal protein as vaccination target based on the
earlier demonstration in animal models that the idio-
typic protein induced protective immunity against the
tumor (24). Importantly, the autologous protein was par-
ticularly immunogenic when presented by dendritic cells
exposed ex vivo to that protein (24). Levy and colleagues
took advantage of that observation and prepared idio-
typic proteins by culturing patients’ lymphoma cells fus-
ed with a mouse–human heterohybridoma cell line (13).
At that time, Levy’s Stanford University colleague
Edgar Engleman had already established methods for
isolation of dendritic cells from peripheral blood and
their ex vivo cultivation (49). Cell isolation was largely
based on density gradient centrifugation of leukaphere-
sis product, the method Levy and colleagues employed
in their study. From the blood of each patient they pre-
pared a monocyte–depleted cell suspension and incubat-
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Figure 1. Dendritic cells. Upper panel: Differential interference con-
trast micrograph of live human mature myeloid dendritic cells demon-
strating characteristic protrusions; Lower panel: scanning electron
micrograph of a dendritic cell interacting with two T cells (arrow). In
both panels, bar=10 µm. From ref. (23) © the American Society of
Hematology.
ed it with autologous idiotype protein for two days.
Treatment schedule included three monthly cycles of the
procedure and one cycle five to six months later; the cycle
consisted of leukapheresis, two-day exposure to antigen
and infusion (37) (Fig. 2). Based on evidence from an
animal model (24), in each cycle immunity was boosted
by subcutaneous injections of the soluble idiotypic pro-
tein. The results were impressive as all four patients
developed cellular immunity to the idiotypic protein ac-
companied by positive clinical effects: one patient was in
complete clinical remission for 21 months, one remained
stable without further therapy, while the other two enjoy-
ed more limited benefit (37).
A company is born!
Concomitant with Levy’s work, in 1992 Engleman
and Samuel Strober, also of Stanford University, founded
Activated Cell Therapy, the company aiming to develop
dendritic cell based cancer therapeutics. The company
chose to develop therapy for castration–resistant prostate
cancer by raising immunity to prostatic acid phosphata-
se. Immunotherapy ought to have fulfilled the need for
therapy specifically at the disease stage when circulating
prostate specific antigen (PSA) levels increase despite
androgen suppression while there is still no pain from
metastases. Among the hoped for advantages of immuno-
therapy was the absence of major adverse events that
could compromise quality of life otherwise acceptable
during that stage of disease.
To develop marketable products, Activated Cell The-
rapy introduced significant technology changes compar-
ed to the technology used by Levy and colleagues. The
aim was to simplify dendritic cell isolation and combina-
tion with antigen. One change was the introduction of
cell–trap centrifugation on a density gradient. The
method uses a patented disposable cell that fits into
standard blood bank centrifuges and traps particular cells
following centrifugation (Fig. 3). The additional feature
of the method is the use of density gradients created by
suspended colloidal organosilanized silica; compared to
more traditional density gradient media, organosilaniz-
ed silica provides higher stability and longer shelf life.
Finally, the company developed the »antigen delivery
cassette«, the fusion protein comprised of the antigen and
a molecule with preferential binding to dendritic cells. In
this project, the antigen has been prostatic acid phospha-
tase (PAP) and the DC-binding molecule the granulo-
cyte-macrophage colony-stimulating factor (GM-CSF;
refs. (9, 58)).
Early clinical trials brought hopes
of success
The hype encircling dendritic cells in the late 1990s
obscured the fact that the cells prepared by the Activated
Cell Therapy (later renamed »Dendreon«) protocol con-
tained no more than one fifth of the cells characterized as
dendritic (bright in CD54 (58), but also in CD40, CD86,
HLA-A,B,C and HLA-DR) while the rest were predomi-
nantly CD3+ T cells combined with monocytes (CD14+)
and B cells (CD19+; ref. (9)). Cell suspensions incubated
with the PAP–GM-CSF construct were tested in two
clinical trials. One, at University of California San Fran-
cisco, administered to patients the cells on three occa-
sions four weeks apart; patients who displayed stable
disease on week 24 received the fourth infusion (59). The
other protocol, at Mayo Clinic in Rochester, Minnesota,
employed two infusions of cells one month apart, but fol-
lowed by three injections of the soluble PAP–GM-CSF
construct (9) based on earlier evidence from animal mo-
dels (24) and the analogy with the study of B-cell lym-
phoma (37).
The results from Mayo Clinic were published in June
2000 (9). The goal of the phase 1 study was to determine
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Figure 2. General scheme of dendritic cell immunotherapy of cancer.
White blood cells are isolated by leukapheresis and further fractionated
to enrich the desired cell population. Most often dendritic cells are
prepared from monocytes. Monocytes (or other cells) are incubated
with a combination of cytokines and other molecules as differentiation
agents and with tumor–associated antigens to generate activated anti-
gen–presenting dendritic cells. These cells are infused or, more often,
subcutaneously injected into the patient.
Figure 3. Cell trap used to prepare sipuleucel-T. The separation contai-
ner is divided by the septum (black) into the lower and upper chamber.
The lower chamber and the lower part of the upper chamber above the
septum (indicated by the dashed line) are filled with colloidal organo-
silanized silica (here designated as BDS60). The cell suspension con-
tained in the blood bag is applied on top of the silica and the device is
centrifuged. Low-density cells concentrate at the interface between the
silica and cell medium in the upper chamber, while higher density cells
are retained in the lower chamber. Modified from Fresenius DACS™
300 instructions leaflet.
treatment safety and, as secondary endpoint, induce the-
rapeutic immunity against prostate-related tissues in pa-
tients suffering from progressive castration-resistant me-
tastatic prostate carcinoma. Altogether thirteen patients
received two autologous antigen-presenting cell infu-
sions and three injections of the soluble synthetic anti-
gen. Patients were divided into three groups, each receiv-
ing a different dose of antigen per injection. Patients
experienced mostly mild adverse events as short-lived
fever and/or chills, myalgia, pain, fatigue or mild local
reactions to soluble antigen injection. In three patients
the levels of circulating PSA dropped as a result of the-
rapy. In addition, therapy induced T cells that could be
activated by GM-CSF and PAP in vitro; this demon-
strated that immune tolerance for GM-CSF and PAP
had been overcome. Injections of soluble antigen had no
effect on T cells, but boosted the titer of antibodies to
GM-CSF and, to a lesser extent, PAP. This study found
no clinical response to treatment, but concluded that
dendritic cells exposed to antigen ex vivo could induce
antigen-specific cellular immunity in prostate cancer pa-
tients. These findings warranted further studies.
The San Francisco study came out in December of the
same year (59). It was a combined phase 1 dose-escala-
tion study and a phase 2 study testing up to four admini-
strations of the cellular product without injections of
soluble antigen. The study included 31 patients alto-
gether. The goals of phase 1 were identical to the study at
Mayo; phase 2 looked for evidence of a delay of pro-
gression of disease. As at Mayo Clinic, patients tolerated
treatment well with similar mild adverse events. A pro-
portion of patients similar to that at Mayo developed
immune response to the recombinant antigen and expe-
rienced a drop in circulating PSA levels. Significantly,
treatment extended the time to disease progression in a
manner positively correlated with the level of immune
response to PAP and the dose of dendritic cells. These
findings infused additional enthusiasm and energy into
this exciting project and resulted in continued studies at
the two institutions.
More good news
In the meantime, Levy’s team continued the studies
in B-cell lymphoma. In 2002 they published the fol-
low-up to their 1996 paper; it included additional 31
patients (65). Generally, the study confirmed earlier re-
sults (37) of durable objective tumor regression and in-
duction of T-cells and antibodies reactive with autolo-
gous idiotypic protein. Interestingly, in patients resistant
to DC vaccination or relapsing after it, the authors could
induce complete tumor regression by injections of soluble
idiotypic protein coupled to keyhole limpet hemocyanin.
This finding seemed to have given additional credence to
the protocol at Mayo Clinic employing injections of so-
luble PAP–GM-CSF to boost immunity against prostate
derived tissues.
In 2004 Mayo Clinic reported the results of the phase
2 study that enrolled 21 patients who received the cellu-
lar product and soluble antigen (10). Two patients ex-
hibited a transient decrease in the levels of circulating
PSA. However, another patient exhibited the reduction
of PSA levels from the high levels of 221 ng/mL to the
levels beyond detection. Even more impressive was the
resolution of his metastatic retroperitoneal and pelvic
adenopathy (Fig. 4) (10) and the fact that he was alive
and free of disease nine years later (personal communi-
cation by Dr. Patrick Burch, Mayo Clinic). Despite an
intense search for the specifics of this patient in com-
parison to those who did not respond, the only difference
was that his peripheral blood mononuclear cells could be
stimulated in vitro with soluble PAP–GM-CSF conside-
rably longer than the cells of other patients. Comparison
of the Mayo Clinic results with those from University of
California San Francisco (59) demonstrated that im-
mune and clinical effects of subcutaneous injections of
PAP–GM-CSF did not differ from the effects of cell
infusion alone (10), contrary to the findings in mice (24)
and patients suffering from B-cell lymphoma (65). For
that reason, further studies were conducted with the
cellular product alone.
Mice are not little humans
The reasons for the observed discrepancy in the ef-
fects of soluble antigens on immune response and effect
on malignancy between mice and humans remain un-
clear. For a long time I questioned the utility of com-
paring experimental murine tumor models and human
cancer; mice are highly inbred, they are kept in patho-
gen-free conditions, live up to two years and usually are
no older than two months when inoculated with the
tumor. Commonly studied transplantable tumors have
been rendered extremely aggressive by numerous pass-
ages that result in survival of the fastest growing cells. On
the other hand, humans are genetically individualized,
carry immunological memory of personal history of in-
flammation and infection, are differently physiologically
»exhausted« by age and disease, and develop tumors that
become manifest after many years of subclinical develop-
ment (26). Svetomir Markovi}, my colleague at Mayo
Clinic, started looking into the relevance of murine mo-
dels and found, for example, that murine and human
dendritic cells responded differently to vascular endothe-
lial growth factor (VEGF), a molecule often borne by
tumors and implied in mechanisms whereby tumors
evade immune surveillance; VEGF, highly immunosup-
pressive in humans is devoid of such effect in mice (7).
Consequently, a cancer immunotherapy protocol can be
greatly more successful in murine models than in hu-
mans. It is thus feasible that such interspecies differences
contribute to difficulties encountered in translation of
immune therapy developed in mice into human clinical
practice.
Towards the proof of efficacy
Individual clinical centers commonly lack the infra-
structure and means to conduct large scale phase 3 clini-
cal trials on their own. Therefore, usually such studies
are conducted by institutional consortia. The first such
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study of the cellular product (now bearing the generic
name sipuleucel-T and commercial name Provenge®),
rather limited in scope, came out in July 2006 (59). The
primary clinical endpoint of the study of 127 patients was
the time to disease progression (determined by radio-
logical observations, onset of pain, neurologic changes,
etc.). It was rather sobering that treatment conferred no
delay in the time to progression, but the overall survival
was extended by 4.5 months. Based on this evidence,
Dendreon Corporation applied to the U.S. Food and
Drug Agency for the license to market the product. To
the disappointment of many and furor of others, the
Agency refused licensure on the grounds that retrospec-
tive data on survival are not sufficient evidence of activity
and requested further prospective studies (3). Conse-
quently, a parallel ongoing phase 3 study was reorga-
nized with survival as the primary endpoint (32). The
study included a control group of patients who also
underwent three therapy cycles two weeks apart, but in
each cycle they received only one third of cells processed
without PAP–GM-CSF (compared to treatment group
that received the full amount of cells prepared with
PAP–GM-CSF); the remaining cells were frozen for the
possible later use.
At the time Mayo Clinic started prostate cancer stu-
dies in the late 1990s, our colleagues in the Division of
Hematology decided to take advantage of the local abi-
lity to prepare autologous antigen presenting cells; they
applied them to patients suffering from multiple myelo-
ma (46). Patients were treated while in remission after
transplantation of autologous bone marrow. They receiv-
ed autologous antigen presenting cells exposed ex vivo to
autologous serum as the source of disease–characteristic
monoclonal protein. Time to progression was the pri-
mary endpoint. Disappointingly, treatment had no effect
on progression. Some years later, prompted by evidence
of extended survival in prostate cancer studies (60), pa-
tient data were revisited; it was found that patients treat-
ed by immunotherapy exhibited the median survival of
5.3 years compared to 3.4 years for patients who had not
received immunotherapy (46). Although the study did
not include a control group, but the results were com-
pared to historic controls, the data indicated the need for
further controlled studies.
By the spring of 2010, Dendreon completed the defi-
nitive phase 3 study that confirmed the survival benefit
observed in earlier studies and obtained the license on
April 29 (18). The data were published the following
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Figure 4. Sipuleucel-T effect on metastases in the prostate cancer patient who underwent a complete clinical response. Left, computerized tomography
scans obtained before treatment and, right, 22 months after initiation of treatment. Arrows indicate the sites of retroperitoneal lymph nodes (upper
panels) and pelvic lymph nodes (lower panels). From ref. (10) © John Wiley & Sons, Inc.
July; the final study found „a relative reduction of 22
percent in the risk of death as compared to the placebo
group … a 4.1 month improvement in median survival
(25.8 months in the sipuleucel-T group vs. 21.7 months
in the placebo group)” (41) (Fig. 5). It took 18 years from
Engleman’s and Strober’s founding of Activated Cell
Therapy to Dendreon’s licensure of sipuleucel-T!
Is it just dendritic cells?
Yet, the questions about the actual mechanism of ac-
tion of sipuleucel-T persist, mainly because of the para-
doxical effect on overall survival without the effect on the
time to progression. In addition, the very benefit of sipu-
leucel-T has been questioned on the basis of possible
errors in the phase 3 study design. Examining the un-
published documents submitted to the U.S. Food and
Drug Administration in the process of obtaining the
marketing permit, it appeared that control patients above
65 years of age lived 11 months less than control patients
younger than 65 (38). This is surprising as such age
difference is not normally observed in prostate cancer
patients at the same stage of disease or in control groups
of other (immuno)therapy studies. In addition, sipuleu-
cel-T extended overall survival in older patients from
17.3 months to 23.4 months, while the difference in
younger patients was less than one month. The authors
speculate that older control patients tolerated the repeat-
ed leukocyte depletion less well than younger patients.
Consequently, the overall survival of the entire control
group was artificially reduced giving the impression of
sipuleucel-T efficacy. This provocative finding needs to
be tested.
Dendreon responded swiftly by a post hoc »explora-
tory« statistical analysis of the effects of PAP–instructed
antigen-presenting cells (derived from the frozen two
thirds of leukapheresis product) on the overall survival
benefit (29). Using the rank-preserving structural failure
time model (30) they estimated »the treatment effect of
sipuleucel-T relative to control had no crossover to [cells
derived from frozen product] occurred.« Had the control
subjects not been compassionately treated and assuming
that the product of frozen cells was equally effective as
the fresh product, the study concluded that sipuleucel-T
extended overall survival by 7.8 months, i.e, almost twice
compared to the results of original analysis of the same
clinical cohorts (29). Nonetheless, the study neither ad-
dressed the fact that control vaccination by one third of
unprocessed mononuclear cells was mechanistically in-
adequate nor that the older control subjects lived less that
would be expected if left untreated (38).
The question of the mechanism has not been ans-
wered for other experimental immunotherapies either.
What is the relationship of tumor–antigen–specific T
cells in patients and clinical response? For a long time it
has been a recognized yet unappreciated fact that tu-
mor–specific T cells arise spontaneously (31, 48). Thus,
even in the absence of any immunotherapy immunity
registers tumor cells, but fails to eliminate them (cf. ref.
(69)). On the other hand, the only other major immune
treatment of immunity is not antigen-specific at all: it is
the intravesically applied Bacille Calmette–Guérin (BCG)
for treatment of muscle non-penetrating bladder carci-
noma (61). Superficially, the two treatments are mecha-
nistically different, yet there is no conclusive evidence
that it is indeed so. The major problem is that the critical
failing element (or elements) of immunity that allowed
tumor development is unknown, as it is the required
status of immunity if effective and predictable eradica-
tion of the tumor is to be achieved.
The clues into the resolution of the latter problem can
come from sources such as the studies correlating im-
mune parameters with survival. For example, the extent
of infiltration of CD8+ T cells into the tumor and the
abundance of these cells and T regulatory cells in some
cases can predict survival (27, 52). This insight prompted
the proposal of »immune score«, a quantifier of the pre-
sence of immune cells in the tumor (52) that can be used
as a predictor of survival and tool for design of »combina-
torial immune-based therapies that reduce tumor-as-
sociated immune suppression to unleash pre-existing or
therapeutically induced tumor immunity« (20).
Another lead came from Avrum Bluming and John
Ziegler of the Uganda Cancer Institute. In 1971 they
reported the case of an eight-year old boy diagnosed with
Burkitt’s lymphoma (8). Ten days after diagnosis and
before any treatment for lymphoma had been commenc-
ed, the boy developed skin rash characteristic of measles
infection; the infection was subsequently confirmed by
the appearance of measles-specific antibodies (8). The
authors reported that »over the course of the next two
weeks both the exanthem and the tumour disappeared«.
Although Bluming and Ziegler gave no definitive mecha-
nistic explanation of the curative effect of measles infection,
their dramatic observation has not remained unnoticed.
Subsequent appreciation of the oncolytic properties of
the measles virus, the safety of its vaccine strains and the
role of immunity gave rise to the effort to use genetically
modified measles virus as a means of experimental can-
cer therapy (6, 39).
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Figure 5. Sipuleucel-T (Provenge) extends survival of prostate cancer
patients as determined by a phase 3 study (41). The median survival
benefit was 4.1 months. Modified from Dendreon promotional
material (www.dendreon.com).
Nihil novi sub sole
The relationship among infection, immunity and ma-
lignancy has been recognized well before the advent of
modern science. Between 1775 and 1980 there have been
449 documented cases of »spontaneous« tumor regres-
sions in patients suffering from some concurrent acute
infection (16). These observations led to the development
and use of nonspecific immune boosts such as Coley’s
toxins (a bacterial extract) in the early 20th century (67)
and the efforts to engage immunity by adjuvants such as
BCG (66) or purified bacterial products (57). However,
this mode of therapy mostly fell into oblivion reminiscent
of the abandonment of bacteriophage therapy of bacte-
rial infection (56) in the wake of development of anti-
biotics. It is plausible that the well known Lewis Thomas’s
notion that »the phenomenon of homograft rejection
will turn out to represent a primary mechanism for na-
tural defense against neoplasia« (64) was not only the
impetus for the formulation of the theory of immune
surveillance (11), but also for the push of nonspecific
immunotherapy into (at least temporary) oblivion. Yet, it
turns out that »nonspecific« mechanisms can act, in part
at least, by affecting antigen presentation by dendritic
cells (40).
A notion inherent in the concept of immune sur-
veillance is that immunity »searches« for particular sig-
natures of cancer that can be characterized in molecular
terms. In concert with the dominating reductionist and
particularistic approach of biomedical science of the 20th
century, the ensuing scientific advances have focused in
large part on the molecular characterization of cancer
cells and definition of molecular targets of immune attack
(cf. refs. (68, 69)). (For an enlightened and entertaining
critique of reductionism, see ref. (42)). This effort has
been quite successful as it resulted in characterization of
numerous tumor–associated epitopes (cf. ref. (19)). Yet,
manifestation of malignancy implies––in contrast to the
acute phase of an infection by a single microbe popu-
lation––that an entire regulatory system failed. Far from
trivializing the effort and success of therapies based on
particular molecular targets, it does appear that the effort
towards more effective cancer treatments must be based
on insights facilitated by systems approaches (28).
The riddle of survival benefit
The finding that sipuleucel-T affects survival, if it
does (38), but not disease progression is not unique.
Other examples include similar observations in post-
-transplant multiple myeloma (46) and a phase 2 study
investigating the effects of an allogeneic prostate cancer
whole-cell vaccine (51). In the latter study, castration-
–resistant prostate cancer patients were vaccinated by 14
subcutaneous administrations over a year. The vaccine
consisted of three lethally irradiated allogeneic human
prostate-derived cell lines; the first two administrations
contained also BCG. The study was not controlled, i.e.,
the results were compared to historic data, rather than to
a group concomitantly treated by placebo. Interestingly,
the study found that vaccination doubled the time to di-
sease progression »as defined by clinical and/or radiologic
criteria« (51). The patients responded also by slowing the
rate of PSA level increase (»PSA velocity«) and exhibited
a more pronounced Th1 (cell–mediated cytotoxic) charac-
ter of immunity compared to non-responders. The en-
suing controlled phase 2 study, using time to progression
as endpoint again, failed at interim analysis (i.e., conti-
nuation of the study had no chance of achieving statistical
significance) and was discontinued. However, years later
an a posteriori analysis demonstrated that patients in this
trial lived six months longer compared to placebo treated
controls (personal communication from Dr. Anthony
Walker, Alacrita Consulting, London, England).
Chemotherapy may not be the right
paradigm for immunotherapy
The paradox of long-term, but not short-term benefit
of vaccination therapy is supported by observations from
other cancer vaccination studies (cf. ref. (22)). Many
studies were discontinued when interim analysis indi-
cated that the final endpoint could not be reached, yet
subsequent–often anecdotal–evidence indicated survival
longer than expected. Common to all these studies has
been the use of statistical methods developed for studies
of chemotherapy where treatment effects are generally
observed rather promptly. A characteristic of these meth-
ods is that they do not take into account the delayed
separation of survival (Kaplan–Meier) curves for treat-
ment and control groups observed in immunotherapy.
Consequently, there have been efforts to define a »metho-
dological framework to enhance the clinical success of
cancer immunotherapy« (34) and overcome the »critical
hurdles in cancer immunotherapy« (25).
A major issue in clinical studies of dendritic cell vacci-
nes has been the lack of standards for their preparation
and administration. Dendritic cell differentiation, anti-
gen capture and processing and consequent presentation
are complex; depending on the differentiation stage, a
dendritic cell can induce tolerance to an antigen or sti-
mulate immunity against it (5). Cell dose, route of admi-
nistration, number of vaccinations, and the need for ad-
juvants are just the few among parameters that vary from
one clinical trial to another (21). It is not surprising that
the need for standardization has been considered quin-
tessential for further progress. In 2004, Carl Figdor and
colleagues considered and recommended for standardi-
zation the parameters pertinent to vaccine preparation
according to current Good Manufacturing Practices, vac-
cine quality control, patient characteristics, trial design,
documentation and definition of clinical response, de-
scription of clinical outcome, description of immune
parameters before and after vaccination and assays pro-
posed to measure these parameters (21). A particular
problem has been standardization of the required im-
mune parameters as it is still not clear which parameters
reflect the tumor–specific immune function and what
that function needs to be for effective tumor therapy (cf.
ref. (20)). It is evident that such standardization is dif-
ficult among numerous early clinical studies conducted
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worldwide. On the other hand, the (mostly industry
sponsored) multi-institutional phase 3 trials can be stan-
dardized more easily as they are centrally designed and
controlled. Alas, in the still rare phase 3 studies of cellular
immunotherapy the study sponsors are generally inte-
rested in funding just the clinical aspects of the study. For
example, a MedLine search on March 20, 2012 using
keywords »Sipuleucel-T« or »Provenge« had 161 hits;
aside from the aforementioned clinical studies with li-
mited monitoring of immune function, not a single one
deals with immune mechanisms underlying the observ-
ed clinical effects! There is little surprise that a Nature
Biotechnology editorial scolds Provenge as »a success for
clinical and manufacturing brawn over molecular pre-
cision« (4).
More recently, slow progress to clinical success has
been attributed to the absence of realization that the
»methodological framework for immunotherapy deve-
lopment … is distinct from that widely used for chemo-
therapy« (34). The proposed framework for immuno-
therapy includes a new paradigm of distinct steps – from
the proof of principle through toxicity screening, mea-
surement of biologic activity of the vaccine, measure-
ment of immune response in clinical trials, dose and
schedule optimization, setting developmental decision
points, trial design and clinical endpoints. Further, speci-
fic clinical kinetics of immunotherapy must be taken
into account by adjusting endpoints accordingly and by
developing appropriate statistical tools (34).
The broad interest in overcoming the current ob-
stacles to progress of immunotherapy has resulted in
consensus – forging meetings, such as a recent one by the
Society for Immunotherapy of Cancer. Its recommenda-
tions focused on problems related to extrapolation from
murine models to humans, delays due to administrative
hurdles (institutional, administrative and regulatory),
cancer biology (tumor complexity and heterogeneity,
mechanisms of tumor escape from immunity), limited
access to reagents and funding as well as insufficient
number of multidisciplinary teams of scientists and cli-
nicians. Of note, the report focuses on two fundamental
problems: lack of markers of immune response and in-
adequacy of conventional criteria of clinical response for
immunotherapy (25).
Complex systems and simple views
Given the enormous complexity of the system and
numerous unresolved issues, is there a way to a more
rational design of effective cancer immunotherapy? A
new promise arises from considerations of immunothe-
rapy beyond the dose–response paradigm (essentially the
scientifically unjustified translation of the Newtonian
action–reaction principle into immunotherapy), but in
terms of complex systems biology. One example is the
consideration of the role of drug administration schedule
and timing on cytotoxic (35) and immune (53) effects.
Twenty years ago, Zvia Agur noticed that normal cells,
but not malignant cells, divide at a rather constant rate
and developed a mathematical model of the effect of
cytotoxic drugs in a system composed of normal cells and
malignant cells (15). She found that delivering a (short-
-lived) cytotoxic drug at the frequency coinciding with
the period of normal cell division reduced toxicity to
these cells (e.g., hematopoietic precursors) while retain-
ing toxicity for malignant cells. This finding was confir-
med contemporaneously in an animal model (1). Such
studies indicate the benefit of expanding therapeutic
considerations beyond just the intended target cell po-
pulation.
A more recent example took advantage of the obser-
vation that the levels of circulating C-reactive protein
(CRP) could be used as a measure of immune activation
(17). Based on the much more frequent than usual mea-
surements in patients suffering from advanced malig-
nancies, it was discovered that CRP levels fluctuate cycli-
cally with the average period of some seven days. This
observation led to the hypothesis that the oscillations
reflect the time-dependent interactions of immune acti-
vation (e.g., rise of Th1-type effectors) and immune at-
tenuation (e.g., increase in the levels of Treg cells; ref.
(17)). Consequently, the authors postulated that the ef-
fects of immune treatment depended on synchroniza-
tion with CRP oscillations, e.g., the effect of a cytotoxic
drug will be different if administered at the peak of Th1
activity or of Treg cell levels, in accord with Dr. Agur’s sug-
gestion many years earlier for cytotoxic therapy (1, 15).
This hypothesis has been recently tested in eleven
patients suffering from unresectable malignant melano-
ma and treated by temozolomide, a lymphocyte deplet-
ing cytotoxic drug (47, 54). Together with the C-reactive
protein and progression-free survival, 29 humoral and 22
cellular markers of immune functions were measured as
a function of time and analyzed by a specially developed
algorithm. The results demonstrated oscillations in the
ratio of polarized macrophages (M1/M2), cytokine IL-17,
CD11c+/CD14+ cells, etc., mostly with periods of 3, 6, 9
and 12 days. While the small number of subjects makes
the results still preliminary, it is interesting that pro-
gression-free survival was related to the first derivative of
the fitted function on the day of treatment. For example,
progression-free survival was longer when the cytotoxic
drug was administered during a cyclical increase in the
levels of IL-12p70 or decrease in the ratio of M1/M2
macrophages. More extensive clinical testing of this ex-
citing hypothesis is underway. (For an insightful view on
this approach, see ref. (33)).
Is it all in the timing?
Oscillations in tumor–immunity interactions have been
studied within the context of systems theory. For examp-
le, a rather simple model posits that the number of tumor
cells oscillates in time with amplitudes and dampening
characteristics dependent on tumor–associated antigens
and level of immunity (43). Assuming that the mathe-
matical model is a reasonably accurate quantitative descrip-
tion of the biological system, one can computationally
vary the parameters that measure antigen »strength« and
level of immunity and simulate the changes in tumor
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burden under particular conditions and predict condi-
tions that will lead to tumor eradication (43). For therapy
by a single immunomodulator (e.g., cytokine IL-2), cu-
rative doses can be unacceptably toxic. Conceivably, this
problem can be mitigated by combination of several
therapeutic agents, each at the acceptable dose level.
Rational design of a combination therapy protocol
that minimizes toxicity and maximizes efficacy can be
complex. For example, by the application of optimal
control theory one can search for the best strategy of
combining treatments by adjusting their dose and/or
administration schedule. The results of a study simulat-
ing discrete administrations of cytotoxic T cells and IL-2
in treatment of an in silico tumor demonstrate the benefit
of the optimized dose and schedule of each agent separa-
tely and of treatment by both according to a protocol that
takes into consideration efficacy, toxicity, and clinical
feasibility of administration (12). This paradigmatic stu-
dy and many similar ones demonstrate the potential of
computational assessment of the effects of a particular
therapeutic approach under ideal(ized) conditions.
Proof is in the patients
Rarely, if ever, have clinical protocols been designed
with the input of mathematical biologists and even less
frequently have their concepts been tested in prospective
clinical trials. For that reason it is impossible to tell
whether mathematicians’ attempts to model tumor im-
munotherapy are much more than intellectual diversion
or desperate attempts at relevance. Hence, some have
taken the opposite approach, testing new mathematical
formulations against existing clinical data. Surprisingly,
despite the glut of clinical trials testing a myriad of treat-
ments, there are preciously few reports of clinical data
measured with sufficient precision and frequency to make
testing of mathematical models possible. A particular
problem is the quantitative assessment of tumor burden.
One way to partially overcome this problem is to use
surrogate markers, e.g., PSA in metastatic prostate cancer
(however imperfect and misleading it probably is; (55)).
The common approach in cancer therapy modeling
has focused on the description, quantification and con-
sequent prediction of effects in patient populations. Be-
cause patients respond to prostate cancer vaccination
differently (51), it is questionable whether mathematical
modeling can predict the effects of immunotherapy for
individual patients. To address this question, Kronik and
colleagues formulated a mathematical model of basic
interactions among the therapeutic vaccine, immune sys-
tem and prostate cancer cells (45). The simplistic mathe-
matical model (Fig. 6) was established on the implication
that the cellular vaccine interacts with DC precursors
maturing them into antigen-presenting DCs that migra-
te from skin into the lymph node. Antigen–presenting
DCs induce Th1–type immunity resulting in tumor-
–specific cytotoxic cells that kill tumor cells. Eventually,
antigen–presenting DCs give rise to regulatory DCs that
recruit regulatory/inhibitory cells that counter the activi-
ty of tumor–killing cells. Prostate cancer cells propagate
exponentially, while the rate of tumor–cell killing is pro-
portional to the number of cytotoxic cells. Vaccination
was modeled as instantaneous addition of the vaccine at
each injection time.
Using kinetic parameters extracted from the literatu-
re, the model was tested on rather extensive PSA velocity
measurements taken over a year (at each of 14 vaccine
administrations) for each individual patient in the afore-
mentioned clinical study of an allogeneic prostate cancer
whole-cell vaccine (51). (PSA was used as a quantitative
correlate of cancer burden in the absence of a more
pertinent marker and as an indicator of acute pertur-
bation of the tumor by therapy.) The models successfully
described PSA levels measured for individual patients
before and during the initial five to nine treatment cycles
and yielded the values of patient-specific parameters (45);
this process resulted in an individualized model for each
patient. Individualized models successfully predicted the
PSA course during subsequent vaccination cycles in 12
out of 15 patients responding to therapy (Fig. 7). Thus,
the model has been validated, i.e., found that it described
the system within the constraints of its assumptions and
limits of the data (45). It also means, that – within the
same constraint and limits – it had the power of predic-
tion.
As in all patients the disease eventually progressed
(51), the model was used to predict whether a change in
vaccine dose or administration schedule would lead to
more favorable clinical outcome. The goal was to stabi-
lize PSA levels from the moment of model validation to
the planned end of treatment (12 months since incep-
tion). Simulations of the PSA course indicated that pa-
tients differed in the requirement for dose or schedule
modification (Fig. 8) (45); for some, the required modifi-
cation was modest (e.g., doubling the frequency of admi-
nistration), while for some even the maximal clinically
feasible intensification of dose or schedule would not
suffice. Consequently, such patients could be directed to
different treatment modalities.
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Figure 6. Model of simplified interactions of immunity and prostate
cancer (P). V, cellular vaccine; Dm, antigen presenting dermal dendri-
tic cells; DC, mature dendritic cells; DR, ’’exhausted’’ dendritic cells; R,
regulatory/inhibitory cells; C, antigen–specific effector cells (e.g.,
cytotoxic T cells). From ref. (44).
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Figure 7. Validation of individualized models for patients responding to vaccination. Patient-specific best-fit model parameters were derived by fitting
the model to the respective pretreatment PSA values and the initial in-treatment PSA values (red). Subsequent PSA levels (blue) were predicted by
the use of the obtained best-fit parameters. In this figure and Fig. 8 vertical dashed lines indicate the beginning of vaccination treatment on day 0.
Achieving good predictive power required a different size of the training set for each patient. From ref. (45).
Figure 8. Stabilizing PSA levels by model-aided modification of the vaccination regimen. Individualized models for Patients 18 and 21 were used to
predict PSA dynamics after modification of the vaccination regimen within limits deemed clinically possible. Red lines represent the best-fit curves to
PSA dynamics observed under the standard treatment regimen (2.4´107 vaccine cells administered every 28 days); blue lines are the predicted courses
of PSA levels when vaccination regimens is modified. For Patient 18, the simulated effects are shown of the doubling of vaccine dose or reducing the
vaccination interval to 21 days. For Patient 21, the vaccine dose was tripled or vaccination interval halved. From ref. (45).
Into the future
Though still only hypothetical and clinically untest-
ed, in silico success of mathematical models in predicting
the effect of treatment and guiding its personalized opti-
mization led to the conclusion that clinical studies in
immunotherapy (and possibly other treatment modali-
ties) of cancer require a novel approach if immuno-
therapy is to enter the mainstream of cancer treatment
any time soon (2). This will require a new and higher
level of collaboration of mathematicians, basic and trans-
lational scientists, and clinicians who will jointly plan
and design novel clinical studies. These clinical trials
will have to allow for personalized treatment (»P-trials«)
that is currently beyond the format recognized by regula-
tory authorities. In the future, authorities will have to per-
mit personalized doses and schedules within a restricted
range (instead of the currently standard testing of the
population response to a fixed dose and schedule).
To facilitate this transition, we proposed a novel com-
putational algorithm that allows mechanism–based real–
time dynamic treatment personalization (Fig. 9) (44).
Briefly, based on the available preliminary data and bio-
logical evidence, one designs the general mathematical
model and criteria for success of its validation. Sub-
sequently one accumulates personal clinical data as
treatment progresses and repeats model personalization
and assesses its validation until the criterion of validation
success is satisfied. Then one employs the validated mo-
del to predict treatment outcomes and suggest treatment
modification (44). If successful in the clinic, the method
will allow response–based adjustments of vaccine dose
and/or administration schedule in the course of treat-
ment and will be useful in stratifying patients with res-
pect to the likelihood of clinical response. As the methods
for noninvasive measurements of tumor burden become
more available and precise, this approach will be more
easily testable.
Epilogue
The vast effort invested into immunotherapy of can-
cer over the past century has not paid off yet; it has not
made immune treatment definitive and has not brought
it to the standard of care. Here I mused on the increasing
understanding of malignancy not as analogous to infec-
tion, but as system failure. This understanding is starting
to yield results. Systems–based approaches are leading to
the appreciation of the role of the dynamic nature and
evolutionary character of interactions of malignancy and
the patient. In that, we are becoming increasingly aware
of the role of individual history of infection and im-
munity, age, individuality of the tumor, and the dyna-
mism of their interactions. We are progressively less puz-
zled by the centuries-old and some recent reports of
»miraculous spontaneous« cure of cancer and are start-
ing to understand mechanisms linking acute infection,
immunity and cancer. The hope seems to be well founded
that the current generation of physicians and scientists
will accomplish in cancer immunotherapy a level of
success commensurate to that by Academician Iki} and
his generation in immunization directed at control of
infectious disease.
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Figure 9. At Stage 1, a general mathematical model and the success validation criteria are designed, based on available preliminary data and biological
insight. At Stage 2, new personal clinical data are collected and model personalization and validation assessment are repeated until the success of
validation criterion is satisfied. Then, at Stage 3, the validated model is used to predict treatment outcomes and suggest treatment modification.
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